BI's DPP-4 inhibitor linagliptin sails through pivotal trials as it chases the pack
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's anti-diabetic linagliptin met its primary endpoint in four Phase III trials in patients, show detailed results presented at the American Diabetes Association (ADA) meeting in Orlando, Florida. The DPP-4 inhibitor outperformed placebo in four different type 2 diabetes settings – as monotherapy, in combination with metformin, with Takeda's Actos (pioglitazone) and with metformin plus sulfonylurea.